ALLO

Allogene Therapeutics, Inc. (ALLO) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic ("off-the-shelf") T cell product candidates for cancer and autoimmune diseases. The company is currently prioritizing four core programs: cema-cel (ALLO-501A) for large B-cell lymphoma and CLL, ALLO-316 for renal cell carcinoma, ALLO-329 for autoimmune diseases, and ALLO-647 (an anti-CD52 antibody for lymphodepletion).

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 11% in Q2 and 22% YTD compared to the prior year periods. This was driven primarily by a 22% workforce reduction initiated in January 2024, resulting in lower personnel costs and stock-based compensation.
• Asset Impairment: The company recorded a $5.0 million pre-tax impairment charge in Q2 2024 related to a leased building in South San Francisco that was vacated and is being marketed for sublease. No such charge was recorded in the prior year.
• Capital Raise: In May 2024, the company completed a registered offering, selling approximately 37.9 million shares for net proceeds of $105.3 million. Additionally, the company raised $1.0 million via ATM offerings and received $2.3 million from a CIRM award.
• Interest Income: Interest and other income increased significantly (32% in Q2, 79% YTD) due to higher yields on the company's cash and investment portfolio.

Guidance, Outlook, and Risks

• Clinical Milestones: The company initiated the pivotal Phase 2 ALPHA3 trial for cema-cel in June 2024, targeting first-line consolidation for large B-cell lymphoma. Enrollment is expected to complete in the first half of 2026, with a BLA submission targeted for 2027.
• Liquidity: Management expects cash and investments of $444.6 million to fund operations for at least the next 12 months. However, the company anticipates continuing to incur net losses and will require additional capital to fully implement its business plan.
• Internal Control Material Weakness: The company identified a material weakness in internal controls over financial reporting related to the technical accounting analysis of significant non-routine transactions (specifically regarding the Allogene Overland joint venture). Remediation is ongoing.
• Strategic Agreements:
  • Servier: Expanded licensed territory to include the EU and UK, increasing potential market opportunity for cema-cel by over 50%.
  • Notch Therapeutics: Ownership interest diluted to 13%; accounting treatment changed from equity method to cost method.
  • Overland Therapeutics: Organizational restructuring resulted in a gain of $1.1 million and a change in ownership structure.
• Risks: Key risks include the failure of clinical trials to demonstrate efficacy/safety, reliance on third-party manufacturing, potential disputes with licensors (Servier/Cellectis), and the need for future financing.

Investor Verification Checklist

• Verify the timeline and enrollment progress of the ALPHA3 pivotal trial, as this is the primary driver for future commercialization.
• Monitor the status of the material weakness in internal controls and the effectiveness of remediation efforts.
• Assess the impact of the Servier-Cellectis arbitration on the company's rights to the CD19 product candidates (cema-cel).
• Track the company's cash burn rate relative to the $444.6 million cash balance to determine the timing of future capital raises.
• Review the status of the sublease for the impaired South San Francisco property to confirm the realization of the impairment charge.